Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells
Sign Up to like & getrecommendations! Published in 2022 at "Scientific Reports"
DOI: 10.1038/s41598-022-09964-6
Abstract: Cholangiocarcinoma (CCA) is a lethal cancer with rapid progression and poor survival. Novel and more effective therapies than those currently available are, therefore, urgently needed. Our research group previously reported the combination of gemcitabine and… read more here.
Keywords: cytotoxicity; cca cells; treatment; combination gemcitabine ... See more keywords
Abstract CT136: Phase Ib study of Decitabine in combination with Gemcitabine in treatment of refractory pancreatic adenocarcinoma and advanced soft tissue or bone sarcomas
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-ct136
Abstract: Background and Objectives: Metastatic pancreatic adenocarcinoma is the second leading cause of cancer related death in the US with limited therapeutic options. Preclinical data have shown that methylation alongside other epigenetic modifications play a role… read more here.
Keywords: phase; combination gemcitabine; pancreatic adenocarcinoma; decitabine combination ... See more keywords
Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
Sign Up to like & getrecommendations! Published in 2018 at "BMC Cancer"
DOI: 10.1186/s12885-018-4872-x
Abstract: BackgroundThe combination of gemcitabine and docetaxel (GT) has been demonstrated to be effective against various types of solid tumors, including sarcoma. However, the regimen has not been confirmed in large, well-designed clinical trials in refractory… read more here.
Keywords: gemcitabine docetaxel; metastatic osteosarcoma; combination gemcitabine; refractory metastatic ... See more keywords
Metabolism-based GP-2250 in combination with gemcitabine as a novel approach to pancreatic cancer: A mouse xenograft study.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e16750
Abstract: e16750Background: GP-2250, a novel oxathiazine derivative, displayed apoptotic cytotoxicity against various tumor cell lines but not normal cells. It was therefore tested whether its antineoplastic... read more here.
Keywords: metabolism based; gemcitabine novel; combination gemcitabine; based 2250 ... See more keywords
A phase Ⅰ open-label dose-escalation study of AL2846 in combination with gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.e16210
Abstract: e16210 Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with a 5-year survival rate of 10%. Overexpression of c-Met is associated with the poor prognosis in patients with PDAC and it was noted… read more here.
Keywords: dose; combination; gemcitabine patients; gemcitabine ... See more keywords